Injectable supramolecular hydrogel shows promise for neoadjuvant immunotherapy of triple-negative breast cancer

The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of cytotoxic T lymphocytes (CTLs). Although neoadjuvant chemotherapy together with immunotherapy has been approved for advanced TNBC, its efficacy is still unsatisfactory, possibly due to systemic treatment-induced lymphatic system disorders and upregulation of additional immune checkpoints in the tumors.